Researchmoz added Most up-to-date research on "Chemotherapy Induced Neutropenia (CIN) - Market Insights, Epidemiology and Market Forecast-2023" to its huge collection of research reports.
DelveInsight’s “Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and Market Forecast-2023” Report provides an overview of the disease and global market trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW). The Report covers the therapeutics market revenue, treatment practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report provides the historical and forecasted data of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 Cancer indications till 2023.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1045347
The report covers the number of patients for 10 cancer indications (i.e. Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin’s disease and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse event of the chemotherapies of respective cancers. Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute
to majority of the market size, of CIN. However, New Chemical Entities are expected to launch in the near future. According to DelveInsight, the Global Market size of CIN in 2016 was USD 3.67 Billion.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Table of Content
Report Introduction
Chemotherapy Induced Neutropenia (CIN) Market Overview at a Glance
Global Market Size of CIN in 2016
Global Market Size of CIN in 2023
Chemotherapy Induced Neutropenia (CIN)
Overview
Causes of Neutropenia
Common cycle of chemotherapy-related neutropenia
Signs and symptoms
Risk Factors
Severity and Grades of Neutropenia
Pathophysiology/ Mechanisms of action
Diagnosis
Epidemiology and Patient Population
Assumptions and Caveats
United States
Incident Cases of ten major Cancer indications in United States
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in United States
Ten major cancer patients at low risk of CIN in United States
Ten major cancer patients at intermediate to high risk of CIN in United States
Europe
Germany
Incident Cases of ten major Cancer indications in Germany
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in Germany
Ten major cancer patients at low risk of CIN in Germany
Ten major cancer patients at intermediate to high risk of CIN in Germany
United Kingdom
Incident Cases of ten major Cancer indications in United Kingdom
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in United Kingdom
Ten major cancer patients at low risk of CIN in United Kingdom
Ten major cancer patients at intermediate to high risk of CIN in United Kingdom
Italy
Incident Cases of ten major Cancer indications in Italy
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in Italy
Ten major cancer patients at low risk of CIN in Italy
Ten major cancer patients at intermediate to high risk of CIN in Italy
Spain
Incident Cases of ten major Cancer indications in Spain
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in Spain
Ten major cancer patients at low risk of CIN in Spain
Ten major cancer patients at intermediate to high risk of CIN in Spain
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1045347
DelveInsight’s “Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and Market Forecast-2023” Report provides an overview of the disease and global market trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW). The Report covers the therapeutics market revenue, treatment practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report provides the historical and forecasted data of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 Cancer indications till 2023.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1045347
The report covers the number of patients for 10 cancer indications (i.e. Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin’s disease and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse event of the chemotherapies of respective cancers. Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute
to majority of the market size, of CIN. However, New Chemical Entities are expected to launch in the near future. According to DelveInsight, the Global Market size of CIN in 2016 was USD 3.67 Billion.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Table of Content
Report Introduction
Chemotherapy Induced Neutropenia (CIN) Market Overview at a Glance
Global Market Size of CIN in 2016
Global Market Size of CIN in 2023
Chemotherapy Induced Neutropenia (CIN)
Overview
Causes of Neutropenia
Common cycle of chemotherapy-related neutropenia
Signs and symptoms
Risk Factors
Severity and Grades of Neutropenia
Pathophysiology/ Mechanisms of action
Diagnosis
Epidemiology and Patient Population
Assumptions and Caveats
United States
Incident Cases of ten major Cancer indications in United States
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in United States
Ten major cancer patients at low risk of CIN in United States
Ten major cancer patients at intermediate to high risk of CIN in United States
Europe
Germany
Incident Cases of ten major Cancer indications in Germany
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer indications in Germany
Ten major cancer patients at low risk of CIN in Germany
Ten major cancer patients at intermediate to high risk of CIN in Germany
United Kingdom
Incident Cases of ten major Cancer indications in United Kingdom
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in United Kingdom
Ten major cancer patients at low risk of CIN in United Kingdom
Ten major cancer patients at intermediate to high risk of CIN in United Kingdom
Italy
Incident Cases of ten major Cancer indications in Italy
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in Italy
Ten major cancer patients at low risk of CIN in Italy
Ten major cancer patients at intermediate to high risk of CIN in Italy
Spain
Incident Cases of ten major Cancer indications in Spain
Incident Cases of Chemotherapy Induced Neutropenia based on ten major Cancer
indications in Spain
Ten major cancer patients at low risk of CIN in Spain
Ten major cancer patients at intermediate to high risk of CIN in Spain
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1045347
No comments:
Post a Comment